VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALEC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALECAlector, Inc.
$2.56$284M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksALECCash Flow

Alector, Inc. (ALEC) Cash Flow Statement

10Y historyFree accessUpdated daily

Free cash flow has been negative for all ten reported quarters, with cumulative operating cash outflows of roughly -$498M against -$308M of net losses—driven by ~-$268M of working capital absorption—leaving $59.9M of cash and no capacity for dividends, buybacks, or acquisitions.

Income StatementBalance SheetCash FlowRatios

ALEC Cash Flow Statement

Annual statement

ALEC Cash Flow Statement

Alector, Inc. (ALEC) cash flow statement — 10-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Cash from Operations-149.88M-184.03M-229.91M-184.16M-20.33M298.55M-166.73M-99.31M127.46M-17.77M-12.99M
Operating CF Margin %--874.46%-228.63%-189.74%-15.21%144.17%-790.28%-468.01%460.54%-475.8%-3123.32%
Operating CF Growth %98.22%19.95%-24.84%-805.91%-106.81%279.06%-67.9%-177.91%817.26%-36.77%-
Net Income41.41M-142.93M-119.05M-130.39M-133.31M-36.33M-190.23M-105.39M-52.25M-32.48M-15.11M
Depreciation & Amortization3.96M9.66M8.84M8.85M8.47M8.31M7.26M5.57M1.02M680K201K
Stock-Based Compensation12.36M26.66M39.46M42.8M46.15M40.78M30.52M16.28M6.92M5.35M1.96M
Deferred Taxes00000000000
Other Non-Cash Items-195.48M-3.36M-12.17M-15.27M-1.16M2.1M929K-3.5M-2.59M6.78M1.88M
Working Capital Changes-12.13M-74.06M-146.99M-90.15M59.53M283.68M-15.22M-12.27M174.36M8.68M-47K
Change in Receivables0002.59M4.8M-7.39M00238K-20K-218K
Change in Inventory000000002.45M6.58M-560K
Change in Payables-3.62M-524K-1.44M-377K-572K1.92M2.41M152K-809K-41K708K
Cash from Investing153.76M196.6M107.13M101.92M-159.01M-49.66M-105.05M-48.87M-224.12M-801K-2.25M
Capital Expenditures-149K-41K-1.25M-2.38M-4.12M-3.25M-5.03M-15.27M-1.88M-801K-2.25M
CapEx % of Revenue0.09%0.19%1.25%2.45%3.08%1.57%23.85%71.94%6.81%21.45%540.87%
Acquisitions000000100.02M0000
Investments-----------
Other Investing300K00000-100.02M0-222.24M00
Cash from Financing-4.91M20.21M81.54M2.55M4.51M30.3M232.11M172.35M131.15M-15K-77K
Debt Issued (Net)009.39M00000000
Equity Issued (Net)5.47M20.21M71.11M2.55M4.51M0224.6M172.35M000
Dividends Paid00000000000
Share Repurchases48K0000000-1.9M-15K-77K
Other Financing-10.38M01.04M0030.3M7.51M0131.15M-15K-77K
Net Change in Cash-1.03M32.78M-41.23M-79.69M-174.83M279.18M-39.67M24.17M34.49M-18.59M-15.32M
Free Cash Flow-150.02M-184.07M-231.16M-186.54M-24.45M295.3M-171.77M-114.57M125.58M-18.57M-15.24M
FCF Margin %-86.48%-874.66%-229.88%-192.19%-18.3%142.6%-814.13%-539.95%453.73%-497.24%-3664.18%
FCF Growth %24.07%20.37%-23.92%-663.08%-108.28%271.92%-49.92%-191.24%776.18%-21.84%-
FCF per Share-1.35-1.79-2.39-2.23-0.303.67-2.21-1.861.84-0.36-1.79
FCF Conversion (FCF/Net Income)-3.62x1.29x1.93x1.41x0.15x-8.22x0.88x0.94x-2.44x0.55x0.86x
Interest Paid1.04M855K000000000
Taxes Paid00000000000

Key Metrics

Growth RegimeContracting
ProfitabilityWeak
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Working capital drain outpaces revenue collapse

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Cash Burn Exceeds Accounting Losses

Based on Alector's quarterly cash flow statements, the operating cash flow to net income ratio has averaged 1.62 over ten quarters, indicating cash outflows materially exceed reported losses — a divergence driven almost entirely by persistent working capital absorption that accrual-based revenue recognition does not capture.

The most extreme divergence occurred in 2024Q4 when Alector reported only -$2.1M of net income yet consumed -$55.0M in operating cash flow, a 26.5x ratio inflated by $62.7M of working capital outflows. This pattern — where cash burn substantially outpaces the accrual-based loss — suggests that even as revenue recognition produces smaller reported losses, the underlying cash collection cycle may be deteriorating faster than the income statement reflects. For a pre-commercial biotech, this gap between accrual losses and cash reality is a material indicator that reported financial performance may understate the true pace of capital consumption.

Cost Cuts Slow but Cannot Reverse Burn

According to Alector's reported financials, quarterly free cash flow burn has decelerated from -$63.1M in 2024Q2 to -$34.2M in 2026Q2, reflecting aggressive R&D retrenchment, yet cumulative cash outflows over the last four quarters still total -$158M with no quarter of positive free cash flow across the ten-quarter window.

The burn reduction tracks the 64% R&D cut documented in the income statement analysis, but FCF margins remain deeply negative at -10.3% in the most recent quarter, and the improvement appears to be a function of cost reduction rather than any operating recovery. Notably, the margin trajectory is erratic — -101.8% in 2024Q4 versus -47.7% in 2026Q1 — reflecting lumpy milestone revenue against a more stable cost base. Investors should note that without revenue inflection or partnership milestones, the burn trajectory implies continued reliance on existing cash reserves rather than self-funded operations, and any further spending reductions risk impairing pipeline value.

Working Capital Dominates Cash Drain

As reported in Alector's SEC filings, working capital changes have consumed between -$5.1M and -$62.7M per quarter over the ten-quarter period, totaling approximately -$268M cumulative — far exceeding the -$20M cumulative depreciation and amortization, confirming that operational cash absorption is driven by receivables dynamics rather than fixed asset intensity.

The outsized working capital outflows — peaking at -$62.7M in 2024Q4 and -$33.3M in 2024Q1 — appear consistent with a collaboration-revenue model where large milestone payments create outsized receivables that subsequently unwind as partnerships wind down. As revenue has collapsed from $54.2M in 2024Q4 to $3.3M in 2026Q2, working capital outflows have moderated to -$15.5M in 2026Q2 but remain negative in every single quarter, suggesting residual collection headwinds or accrual reversals persist even after the revenue base has largely evaporated. A return to a single positive working capital quarter would be an early indicator that the cash drain is finally normalizing.

Near-Zero Capex Leaves No Reinvestment Base

Reported capital expenditures across Alector's ten-quarter window never exceeded -$533K, with 2026Q2 capex of just -$31K against -$2.0M of depreciation and amortization, indicating essentially no reinvestment in fixed assets — consistent with an asset-light R&D model where program spend flows through operating expense rather than capital accounts.

The near-total absence of capital spending means capex contributes essentially nothing to the free cash flow deficit — 2026Q2 FCF of -$34.2M is effectively identical to operating cash flow. This is structurally appropriate for a discovery-stage biotech, but it also means depreciation is running well above replacement investment, so any reacceleration of pipeline activity would require fresh cash outlays that would not show up in historical capital intensity ratios. With CapEx/Rev appearing volatile (0.9% to 11.3%) purely because the revenue denominator has collapsed, these ratios should be treated as uninformative rather than as evidence of capital discipline.

Accumulated Losses Understate Cash Reality

Across ten reported quarters, Alector's cumulative net losses of approximately -$308M compare to cumulative operating cash outflows of roughly -$498M, a $190M gap that indicates cash consumption has run roughly 61% higher than the accrual-based loss suggests, driven by working capital absorption that appears unlikely to reverse.

This persistent gap between cumulative earnings and cumulative cash consumption suggests the accounting loss, while substantial, does not fully capture Alector's economic capital destruction. The divergence appears structural rather than timing-driven, given that it appears in every quarter without reversal, and implies that any investment thesis anchored on the reported net loss figure may be understating the true cash burn rate that will continue until partnership revenue is re-established or operations are further curtailed. The cumulative magnitude matters: roughly $190M of cash consumed beyond reported losses represents real dilution risk if the company must return to capital markets.

Zero Returns, Pure Cash Conservation

Based on Alector's reported cash flow activities, the company has deployed zero capital toward dividends, share repurchases, or acquisitions across all ten quarters, with the entirety of available cash consumed by operating losses and working capital requirements, leaving no residual capacity for strategic redeployment or shareholder returns.

This deployment profile is consistent with a company in survival mode, prioritizing cash preservation over any form of capital return or inorganic growth. While the absence of buybacks may appear conservative, it also signals that the board and management may view liquidity as insufficient to support even modest return-of-capital programs, reinforcing the thesis that Alector's cash runway is the binding constraint on strategic optionality rather than a deliberate capital allocation choice.

What the Cash Flow Statement Obscures

According to ALEC's reported filings, non-cash stock-based compensation fell from $10.3M in 2024Q1 to $2.6M in 2026Q2 while depreciation of roughly $2.0M per quarter exceeds capital spending, and recurring non-operating income repeatedly cushions net losses below operating losses — components that complicate any simple read of the burn.

Three adjustments warrant scrutiny before drawing conclusions from the headline burn. First, the 75% reduction in stock-based compensation means historical operating cash flow benefited from a non-cash add-back that is now shrinking, so the underlying cash burn may be improving slightly less than the operating line suggests. Second, net losses have consistently printed smaller than operating losses (for example -$23.0M net versus a -$24.4M operating loss in 2026Q2), implying recurring non-operating income — likely interest income on the cash balance — that will decay as reserves are drawn down, making future net losses appear worse independent of operations. Third, the working capital line is reported net and may mask offsetting swings between receivables, prepaid expenses, and accrued liabilities, so a single -$15.5M figure does not reveal which accounts are draining cash. These items suggest investors should monitor the composition, not just the magnitude, of the operating cash deficit.

ALEC — Frequently Asked Questions

Quick answers to the most common questions about buying ALEC stock.

How much cash does Alector, Inc. (ALEC) generate from operations?

Alector, Inc. (ALEC) generated $-184.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Alector, Inc.'s free cash flow?

Alector, Inc. (ALEC) reported negative free cash flow of $184.1M in 2025, indicating capital requirements exceeded cash from operations.

What is Alector, Inc.'s capital expenditure (CapEx)?

Alector, Inc. (ALEC) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.